SAT0465 An integrated safety data analysis across all phase ii and phase iii clinical programs for ustekinumab in psoriatic arthritis, crohn's disease, and psoriasis
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1116
Abstract: Objectives Therapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in patients (pts) with psoriatic arthritis (PsA), Crohn's disease (CD),… read more here.
Keywords: phase; employee janssen; pbo; safety ... See more keywords
THU0360 Improvements in sleep problems and pain in patients with active ankylosing spondylitis treated with intravenous golimumab: 28-week results of the phase iii go-alive trial
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5325
Abstract: Objectives To investigate the effect of intravenously administered (IV) Golimumab (2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain, and night back pain in adult patients (pts) with active Ankylosing Spondylitis (AS).… read more here.
Keywords: employee janssen; research; back pain; sleep problems ... See more keywords
OP0229 GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.1240
Abstract: Guselkumab (GUS), an IL-23 inhibitor monoclonal antibody (Mab) that specifically binds to the IL-23p19 subunit, demonstrated efficacy compared to placebo (PBO) in reducing skin and musculoskeletal signs and symptoms in patients (pts) with active psoriatic… read more here.
Keywords: janssen research; effector cytokines; 17a 17f; employee janssen ... See more keywords